CD47

CD47

CD47 Overview

Molecule Name
Cluster of differentiation 47
Synonyms
CD47,MER6,IAP,OA3
Drug Development Progress
Drugs in Clinical Trials48
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
MER6,CD47,Leukocyte surface antigen CD47,CD47 Molecule,Antigenic Surface Determinant Protein OA3,CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer),Antigen Identified By Monoclonal Antibody 1D8,Integrin Associated Protein,Rh-Related Antigen,CD47 Glycoprotein,IAP,Integrin-Associated Signal Transducer,Protein MER6,OA3,CD47 Antigen,Integrin-Associated Protein
Background
Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.

CD47 Product List

Species
  • Human(9)
  • Mouse(5)
  • Cynomolgus / Rhesus macaque(4)
  • Canine(1)
  • Rabbit(1)
  • Rat(1)
Tag
  • His Tag(6)
  • Fc Tag(5)
  • His Tag & Avi Tag(4)
  • Fc Tag & Avi Tag(3)
  • Mouse IgG Fc Tag(2)
  • Mouse IgG Fc Tag & Avi Tag(1)
Host
  • HEK293(21)
Conjugate
  • Unconjugated(13)
  • Biotin-labeled(7)
  • FITC Labeled(1)
Grade
  • RUO(21)
Low Endotoxin
  • Yes(7)
  • No(14)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
CD47
Mouse CD47 Protein, Fc Tag (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISA

$360.00

100ug
CD47
Cynomolgus / Rhesus macaque CD47 Protein, His Tag, low endotoxin
Cynomolgus / Rhesus macaque
HEK293
SDS-PAGE
ELISASPRBLI

$360.00

50ug
CD47
Human CD47 Protein, His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLI

$345.00

100ug (50ug X 2)
CD47
Human CD47 Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$445.00

50ug
CD47
HOTAvitag
CD7-H82E9
Biotinylated Human CD47 Protein, His,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISAFlow

$360.00

25ug
CD47
Cynomolgus / Rhesus macaque CD47 Protein, Fc Tag, low endotoxin
Cynomolgus / Rhesus macaque
HEK293
SDS-PAGE
ELISA

$360.00

100ug
CD47
Canine CD47 Protein, His Tag
Canine
HEK293
SDS-PAGE
ELISA

$360.00

100ug
CD47
Avitag
CD7-C82E3
Biotinylated Cynomolgus / Rhesus macaque CD47 Protein, His,Avitag™
Cynomolgus / Rhesus macaque
HEK293
SDS-PAGE
ELISA

$360.00

25ug
CD47
Avitag
CD7-C82F3
Biotinylated Cynomolgus / Rhesus macaque CD47 Protein, Fc,Avitag™ (MALS verified)
Cynomolgus / Rhesus macaque
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
CD47
Human CD47 Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISABLIFlow

$330.00

100ug
You Have Viewed 1-10 Of 21 Results
  • 1
  • 2
  • 3

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
CD47 Monoclonal AntibodyMonospecific antibodyOncology/CancerAdvanced solid tumor,Advanced hematological tumorINDGlobal
Drug Type
Monospecific antibody
Therapeutic Area
Oncology/Cancer
Indication
Advanced solid tumor,Advanced hematological tumor
Stage
IND
Rights Area
Global
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IMC-002(Immuneoncia)IMC-002; 3D-197; 3D197Phase 3 ClinicalImmuneoncia Therapeutics Inc
Hematologic Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Neuromyelitis Optica; Solid tumours; Stomach Neoplasms
Details
TimdarpaceptIMM01; IMM 01; IMC-001Phase 3 Clinical
Atherosclerosis; Cardiovascular Diseases; Hematologic Neoplasms; Hodgkin Disease; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Solid tumours
Details
EvorpaceptALX148; ALX-148Phase 3 ClinicalAlexo Therapeutics
Carcinoma, Transitional Cell; Composite Lymphoma; Esophageal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Oropharyngeal Neoplasms; Plasmablastic Lymphoma; Primary mediastinal B cell lymphoma; Richter's Syndrome; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms
Details
Amulirafusp alfaIMC-002; IMM-0306Phase 3 Clinical
Glomerulonephritis, Membranous; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Nephrosis; Neuromyelitis Optica
Details
LigufalimabAK-117Phase 3 Clinical
Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Esophageal Neoplasms; Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma; Myelodysplastic Syndromes; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
Magrolimab5F9; Hu5F9-G4; ONO-7913; GS-4721Phase 2 ClinicalStanford University
Brain Neoplasms; Carcinoma, Transitional Cell; Colorectal Neoplasms; Hodgkin Disease; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Neuroblastoma; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Sezary Syndrome; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
Details
AO-176AO-176; Ti-104; Ti-108; Ti-176Phase 2 ClinicalArch Oncology Inc
Multiple Myeloma; Solid tumours
Details
OntorpaceptTTI-621Phase 2 ClinicalThe Hospital For Sick Children, Trillium Therapeutics Inc, University Health Network (Uhn)
Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Hematologic Neoplasms; Leiomyosarcoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Melanoma; Multiple Myeloma; Mycosis Fungoides; Papillomavirus Infections; Primary mediastinal B cell lymphoma; Sarcoma; Skin Neoplasms; Solid tumours
Details
AUR-103AUR-103Phase 2 ClinicalAurigene
Gastroesophageal Junction Neoplasms; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Solid tumours; Stomach Neoplasms
Details
MaplirpaceptTTI-622; PF-07901801Phase 2 ClinicalTrillium Therapeutics Inc
Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Multiple Myeloma; Ovarian Neoplasms; Peritoneal Neoplasms; Primary mediastinal B cell lymphoma; Skin Neoplasms
Details
DSP-107KAHR-107; DSP-107Phase 2 ClinicalKahr Medical
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Solid tumours
Details
BRB-002BRB-002Phase 2 ClinicalBitterroot Bio Inc
Atherosclerosis; Cardiovascular Diseases; Vasculitis
Details
HCB-101HCB-101Phase 2 ClinicalHanchorBio Inc
Carcinoma, Renal Cell; Colorectal Neoplasms; Lymphoma, Non-Hodgkin; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
LB-101 (Centessa Pharmaceuticals)LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibodyPhase 2 ClinicalCentessa Pharmaceuticals Plc
Solid tumours
Details
SpevatamigPT-886; PT886Phase 2 ClinicalPhanes Therapeutics Inc
Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms
Details
PeluntamigPT-217Phase 2 ClinicalPhanes Therapeutics Inc
Carcinoma, Neuroendocrine; Neuroendocrine Carcinoma of Lung; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours
Details
BCD-106BCD-106Phase 2 ClinicalBIOCAD JSC
Solid tumours
Details
BAT-7104BAT-7104Phase 2 ClinicalBio-Thera Solutions Ltd
Neoplasms; Solid tumours
Details
IMM-2902IMM-2902Phase 2 Clinical
Breast Neoplasms; Cholangiocarcinoma; Lung Neoplasms; Solid tumours; Stomach Neoplasms
Details
6MW-32116MW3211; 6MW-3211Phase 2 ClinicalMabwell (Shanghai) Bioscience Co Ltd
Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Myelodysplastic Syndromes; Neoplasms
Details
JMT-601JMT-601Phase 2 ClinicalShanghai Jmt-Bio Inc
Glomerulonephritis, Membranous; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Nephrosis
Details
LemzoparlimabABBV-IMAB-TJC4; TJ-1133; TJ-011133; TJC-4Phase 2 ClinicalAbbvie Inc, I-Mab Biopharma Co Ltd
Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Solid tumours
Details
Anti-CD47 monoclonal antibody (Biocad)Phase 1 ClinicalBIOCAD JSC
Neoplasms
Details
Recombinant humanized monoclonal antibody MIL95 (Mabworks/Connaught Biomedical Technology)MIL-95; CM-312Phase 1 ClinicalBeijing Mabworks Biotech Co Ltd
Leukemia, Myeloid, Acute; Lymphoma; Neoplasms; Solid tumours
Details
ZeripatamigTG-1801; NI-1701Phase 1 ClinicalNovimmune Sa
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Richter's Syndrome
Details
SL-172154SL-172154; SIRPα -Fc-CD40LPhase 1 ClinicalShattuck Labs Inc
Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
SimridarlimabIBI-322; IBI322Phase 1 Clinical
Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Neoplasms; Solid tumours
Details
anti-CD47 mAb (Hangzhou Sumgen Biotechnology/Zhongsheng Sumgen Biotechnology)SG-404 (Hangzhou Sumgen)Phase 1 ClinicalZhongsheng Shangjian Biological Medicine (Hangzhou) Co Ltd
Hematologic Neoplasms; Solid tumours
Details
anti-CD47/CD20 bispecific antibody (Bristol-Myers Squibb Co)Phase 1 ClinicalBristol-Myers Squibb Company
Hematologic Neoplasms; Lymphoma, Non-Hodgkin
Details
ZL-1201ZL-1201Phase 1 ClinicalZai Lab (Shanghai) Co Ltd
Hematologic Neoplasms; Neoplasms; Solid tumours
Details
HMPL-A83HMPL-A-83; HMPL-A83Phase 1 Clinical
Hematologic Neoplasms; Neoplasms; Solid tumours
Details
NI-1801NI-1801Phase 1 ClinicalLight Chain Bioscience Ltd
Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Solid tumours; Triple Negative Breast Neoplasms
Details
IMM-0306SIMM0306S; IMM-0306SPhase 1 Clinical
Lupus Erythematosus, Systemic
Details
AK-132AK132; AK-132Phase 1 Clinical
Neoplasms; Solid tumours
Details
D3L-001D3L-001Phase 1 ClinicalD3 Bio (Wuxi) Co Ltd
Neoplasms; Solid tumours
Details
FP-002 (Fapon Biopharma)FP-002Phase 1 ClinicalGuangdong Fapon Biopharma Inc
Neoplasms; Solid tumours
Details
BC-007 (Dragonboat Biopharmaceutical)BC-007Phase 1 ClinicalDragonboat Biopharmaceutical
Neoplasms; Solid tumours
Details
SG-1906SG-1906; SG1906Phase 1 ClinicalHangzhou Shangjian Biotechnology Co Ltd
Neoplasms; Solid tumours
Details
LD-002LD-002Phase 1 ClinicalZhejiang Blue Shield Pharmaceutical Co Ltd
Hematologic Neoplasms; Lymphoma, Non-Hodgkin; Solid tumours
Details
SHS-009SHS-009; SH009; SH-009Phase 1 ClinicalNanjing Sanhome Pharmaceutical Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
Monoclonal Antibody (Mab) sB24MPhase 1 ClinicalSwiss Biopharma Med GmbH
Pyoderma; Pyoderma Gangrenosum
Details
IMM-2520IMM-2520Phase 1 Clinical
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
STI-6643STI-6643Phase 1 ClinicalSorrento Therapeutics Inc
Neoplasms; Solid tumours
Details
PF-07257876Phase 1 ClinicalPfizer Inc
Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
TQB-2928TQB-2928Phase 1 ClinicalJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Carcinoma, Non-Small-Cell Lung; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms; Osteosarcoma; Solid tumours
Details
IMM2505IMM2505; IMM-2505Phase 1 ClinicalSunHo (China) BioPharmaceutical Co Ltd
Solid tumours
Details
SG404SG-404; SG404Phase 1 ClinicalHangzhou Shangjian Biotechnology Co Ltd
Neoplasms
Details
Kintuzumab(GenSci)Phase 1 ClinicalChangchun GeneScience Pharmaceuticals Co Ltd
Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Solid tumours
Details
Customer Reviews
  • L***z2026-02-12
    I have been using the protein for ELISA assays, andit has met our experimental requirements without any issues. Low doses are sufficient for coating, which makes the assays cost-effective while still providing strong and consistent signal. The shipping was fast and the product arrived in excellent condition.
  • A***r2023-01-31
    A new ELISA binding was set up with this new recombinant protein. Among the various suppliers evaluated, the one from Acro Biosystem has been selected. Low doses are needed for coating in comparison to other providers. In addition, data quality was confirmed on repeatition runs. Finally, product delivery was quick and the interaction with our local business development manager is highly satisfaying.
  • R***e2022-09-10
    Heard about ACRO from word of mouth from coworkers here at PPD and decided to browse the internet . My team purchased this product for some ELISA testing at the lab. We have been satisfied with the results so far. Great repeatability, sustainability, and specificity as compared to other vendors! It’s very creditable in my opinion. All and all ACRO definitely has some great quality products that are also more cost-effective compared to different vendors like MSD!
  • G***a2021-08-26
    This human CD47-mIgG2aFC worked well in cell based binding assays as determined by flow cytometry. It bound to human SIRP alpha and SIRP gamma expressing cell lines (U87, THP-1, Jurkat T-ALL) as detected by an anti-mouse IgG2a secondary antibody. The binding to SIRP gamma expressing Jurkat cells was reduced when the cells were pre-incubated with SIRP gamma specific antibody clone LSB2.20, as expected.
  • 1***02019-10-25
    I bought this product for ELISA test. The test has good repeatability. Compared to other products I purchased from other vendors, it has better specificity and is more cost-effective. It is a great choice.
  • 1***62019-10-12
    I used this protein to detect mouse serum titer. The product is more cost-effective, good quality, and the obtained data is highly reliable compared to RnD Systems products. In addition, when I performed other ELISA experiments, the data was greatly reproducible.